COVID-19, antibiotics and One Health: a UK environmental risk assessment

  27 August 2020

There is growing interest in the role of secondary bacterial and fungal infections as a cause of increased morbidity and mortality in COVID-19 patients, with reports of up to 95% of COVID-19 inpatients being prescribed antibiotics. Concerns have been raised over the environmental implications of such a large-scale drug administration and statements made about the potential impacts of COVID-19-related antibiotic prescription on antimicrobial resistance (AMR) and other toxicological effects on the environment.

Author(s): Sean D W Comber, Mathew Upton, Shaun Lewin, Neil Powell, Thomas H Hutchinson
Clean Environment  


Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition


JSS University


Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!